Thanks to SA contributor U.S. Biotech for bringing this October 2012 Athersys presentation to my attention. It was presented before a very small group at the Institute of Transplantation, Newcastle upon Tyne. During the Q&A session at about 1:05:30 he discusses interim blinded data from the stroke trial. The presentation speaks for itself and doesn't need any commentary on my part. Share with both supporters and detractors.
Disclosure: I am long ATHX.